India's Piramal adds capacity to U.S. high-potency API site by Eric Palmer Thursday, June 27, 2019 CDMO Piramal Pharma Solutions has completed an expansion at the Michigan site where it makes high-potency APIs.
FiercePharmaAsia—China drug policy, Biocon, C-Bridge by Angus Liu Friday, October 13, 2017 China issued expansive drug policy change guidelines, the FDA rejected Mylan and Biocon's Neulasta biosim, C-Bridge hired ex-GSK exec Hussain.
India's Piramal investing $55M in API production by Eric Palmer Tuesday, October 10, 2017 Indian CDMO Piramal Pharma Solutions is beefing up its global API production, including in the U.S., where it has expanded in recent years.
Piramal bulks up in injectable generics with J&J deal by Phil Taylor Tuesday, October 11, 2016 Piramal added to its run of healthcare acquisitions with a $175 million deal to buy five injectable pain drugs from Johnson & Johnson.
U.S. election on minds of CMO execs at CPhI by Eric Palmer Thursday, October 6, 2016 Though most companies at CPhI are not from the United States, a vast majority of those in attendance have their minds on the U.S. election.
India's Piramal buys another U.S. manufacturer by Eric Palmer Tuesday, August 16, 2016 Piramal, like a number of its Indian compatriots, has decided it is a good idea to have manufacturing operations based in the U.S. and has now snapped up a Midwestern-based CDMO.
